By 8:30 a.m., sacred objects lined the newly clean playroom desk: A Labubu knockoff, a karaoke microphone, half a geode, a ...
Abbott's Medical Devices segment, especially CGM, continues to deliver robust double-digit growth, offsetting Nutrition ...
The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.
Pricing challenges in Abbott’s nutrition business and lower than expected sales of continuous glucose monitors drove down the ...
Discover how UCSF is leading the charge in Long COVID research, uncovering key findings that advance our understanding of the ...
The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.
The 2024-2025 COVID-19 vaccines protected against COVID-19-associated ED and urgent care visits among US pediatric patients.
Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...
New options for testing and treating some of the most common sexually transmitted diseases are becoming available, a trend that experts hope will keep downward pressure on U.S. infection ...
A blood test, combined with an ultrathin material derived from graphite, could significantly advance efforts to detect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results